FRANKLIN LAKES, N.J., July 19, 2011 /PRNewswire/ — Oncology
treatments are not what they were a decade ago. Drugs that
target specific molecular pathways in a cancer cell are being added
to or replacing once standard therapies, requiring a new model of
patient care. Medco Health Solutions, Inc. (NYSE:
MHS) today announced new offerings within its Advanced Oncology
Solutions™, that include treatment pathways decision support
with embedded pharmacogenomic testing and nutrition recommendations
for cancer patients.
Treatment Pathway Connections is the newest component in Medco’s
Advanced Oncology Solution’s platform, which coordinates care among
physicians, pharmacists, case managers and payers, and informs them
of evidence-based protocols before and during treatment.
eviti®, a web-based oncology decision-support program
developed by ITA Partners, Inc.®, will power the treatment plan
decision-support function of the platform.
“Through eviti, our treatment pathway program is able to align
quality care with reimbursement, reduce complexity, provide
transparency and improve workflows for physicians and payers,” said
Jeff Ulanet, vice president oncology. “Our goal is to reduce
the gaps in care that negatively impact patient outcomes and can
lead to unnecessary treatment costs.”
Medco is the first PBM to offer this independent, comprehensive
oncology decision support approach that contains more than 1,000
evidence based treatment regimens for more than 120 cancer types,
displaying efficacy, costs, toxicity and compliance with the
patient’s plan language – all at the moment of prescribing.
ITA Partners, which employs a team of oncologists, oncology
nurses, insurance professionals, actuaries, software designers and
engineers has specialized in oncology de